Wertheimer, G and Bereznicki, LR, Exploring the quality of anticoagulant prescribed for patients with atrial fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, Australia, Journal of cardiovascular pharmacology and therapeutics pp. 1-8. ISSN 1074-2484 (2019) [Refereed Article]
Copyright The Author(s) 2018
Background: Limited data are available on the clinical management of atrial fibrillation (AF) and its outcomes from an Australian perspective.
Objective: To describe the appropriateness of antithrombotic prescribing for patients who presented with a diagnosis of AF to the Hawkesbury St John of God Hospital, New South Wales, Australia.
Methods: This retrospective observational study reviewed patients admitted to St John of God Hawkesbury Hospital with AF between June 2016 and June 2017. We calculated stroke risk using the CHA2DS2-VASc score based on medical records and reviewed the appropriateness of oral anticoagulant (OAC) prescribing compared to the 2016 European Society of Cardiology guidelines. Patients were excluded if they had only 1 episode of AF that reverted either spontaneously or upon cardioversion without any documented recurrences.
Results: A total of 200 patients (18 years) were included, with 180 (90%) deemed eligible for anticoagulation. Of these 72.8% (n = 131) were prescribed an OAC. A total of 40.0% of patients at low risk of stroke and 68.4% at intermediate risk were prescribed an OAC, respectively. Apixaban was the direct OAC of choice with 36.6% of patients prescribed an OAC receiving apixaban. Warfarin was prescribed for 25.1% of the patients who were prescribed an OAC.
Conclusions: The underutilization of anticoagulant medication in high-risk groups and over utilization in low-risk groups remains an ongoing issue in contemporary AF management, and it highlights the need to improve AF-related stroke prevention in our jurisdiction.
|Item Type:||Refereed Article|
|Keywords:||AF, anticoagulants, atrial fibrillation, heart disease, prevention, cardiac arrhythmias|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Pharmacology and pharmaceutical sciences|
|Research Field:||Clinical pharmacy and pharmacy practice|
|Objective Group:||Other health|
|Objective Field:||Other health not elsewhere classified|
|UTAS Author:||Bereznicki, LR (Professor Luke Bereznicki)|
|Year Published:||2019 (online first 2018)|
|Web of Science® Times Cited:||3|
Repository Staff Only: item control page